Qing Yang
Guangzhou University of Chinese Medicine(CN)Nanchang University(CN)Qingdao University of Science and Technology(CN)Guangxi University(CN)Sun Yat-sen University(CN)Duke University(US)Shanghai Jiao Tong University(CN)Xiamen University(CN)Chinese Academy of Sciences(CN)Peking University(CN)Kunming Medical University(CN)Wenzhou Medical University(CN)Wuhan University(CN)Shandong Institute of Automation(CN)Shanghai Ninth People's Hospital(CN)Zhejiang Cancer Hospital(CN)First Affiliated Hospital of Kunming Medical University(CN)Zhongnan Hospital of Wuhan University(CN)The First Affiliated Hospital, Sun Yat-sen University(CN)Northern Jiangsu People's Hospital(CN)Peking University Third Hospital(CN)Jiangsu Province Hospital(CN)Office of Diversity and Inclusion(US)Tongji Hospital(CN)First Affiliated Hospital of Nanchang University(CN)University of Chinese Academy of Sciences(CN)Honghu Hospital of Traditional Chinese Medicine(CN)Huazhong University of Science and Technology(CN)Southern Medical University(CN)Xiamen University of Technology(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
Mobile Health and mHealth Applications, Maternal Mental Health During Pregnancy and Postpartum, Cardiovascular Health and Risk Factors, Cancer Immunotherapy and Biomarkers, Health disparities and outcomes
Most-Cited Works
- → Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma(2021)773 cited
- → Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus(2016)362 cited
- → Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma(2018)216 cited
- → Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study(2018)156 cited
- → Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer(2019)135 cited
- → DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity